PHARMACOGENETICS AND PHARMACOGENOMICS. J. Steven Leeder PharmD, PhD
Pediatric Clinics of North America - Volume 48, Issue 3 (June 2001). doi:10.1016/S0031-3955(05)70338-2.
Hoskins JM, Carey LA, McLeod HL (August 2009). “CYP2D6 and tamoxifen: DNA matters in breast cancer”. Nat. Rev. Cancer9 (8): 576–86. doi:10.1038/nrc2683. PMID19629072.
Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM (June 2003). “Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro”. Drug Metab. Dispos.31 (6): 768–72. doi:10.1124/dmd.31.6.768. PMID12756210.
Foster BC, Sockovie ER, Vandenhoek S, Bellefeuille N, Drouin CE, Krantis A, Budzinski JW, Livesey J, and Arnason JT (2004). “In Vitro Activity of St. John's Wort Against Cytochrome P450 Isozymes and P-Glycoprotein”. Pharmaceutical Biology42 (2): 159–169. doi:10.1080/13880200490512034.
He N, Zhang WQ, Shockley D, Edeki T (February 2002). “Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes”. Eur. J. Clin. Pharmacol.57 (12): 847–51. doi:10.1007/s00228-001-0399-0. PMID11936702.
Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM (June 2003). “Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro”. Drug Metab. Dispos.31 (6): 768–72. doi:10.1124/dmd.31.6.768. PMID12756210.
He N, Zhang WQ, Shockley D, Edeki T (February 2002). “Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes”. Eur. J. Clin. Pharmacol.57 (12): 847–51. doi:10.1007/s00228-001-0399-0. PMID11936702.